A phase III, open-labelm, follow-up study to protocol HIV-NAT 002.1 to explore the durability of the antiretroviral efficacy and durability of ddI/d4T abd AZT/3TC in population originally treated with ddI/d4T, and explore the efficacy of adding hydroxyurea to failing therapy with two nucleosides

To determine durability of the virological and immunological responses of participants on study 002.1 who were…

A randomized, open-label, comparative study to evaluate the efficacy and tolerability of Indinavir/low dose Ritonavir BID versus Indinavir TID as part of combination antiretroviral therapy with CombivirR (AZT+3TC) for the treatment of HIV-1 infection in an antiretroviral pretreated Thai study population

This study will be the first to evaluate a protease inhibitor as part of a triple…

A randomized, open label, study to compare the safety and biological effects of combinations od Didanosine (ddI) and Stavudine (d4T) to Didanosine monotherapy in antiretroviral naïve HIV infected subjects with CD4 cell counts of 150-350 /uL

Previous studies have shown that d4T and ddI given to antiretroviral naïve subjects with CD4 counts…

A randomized, open-label, comparative trial of AZT/3TC versus AZT/3TC/ddI in antiretroviral naïve HIV-1 infected Thai patients

An in vitro study comparing the ability of ten different three-drug combinations to prevent HIV-induced cytopathic…

A randomized, open-label, follow-up study to protocol HIV-NAT 003 to explore the antiviral efficacy and tolerability of immediate switching to therapy with d4T/ddI versus continued AZT/3TC and deferred switching to d4T/ddI in a population pretreated with AZT/3TC for at least 48 weeks and comparing these strategies with immediate switching to therapy with d4T/3TC/Abacavir versus continued AZT/3TC/ddI and deferred switching to d4T/3TC/Aacavir in a population pretreated with AZT/3TC/ddI for at least 48 weeks

To explore the antiretroviral efficacy and tolerability of therapy with d4T/ddI in patients pretreated with AZT/3TC…

A randomized, open-label, comparative trial of AZT/3TC/ddI om antiretroviral naïve HIV-1 infected in Thai patients

An in vitro study comparing the ability of ten different three-drug combinations to prevent HIV-induced cytopathic…

A randomized, open-label follow-up study of protocol HIV-NAT 001 to explore the antiretroviral efficacy and tolerability of switching to therapy with d4T/ddI/Saquinavir soft gel capsules versus Combivir (AZT/3TC)/Saquinavir soft gel capsules in an HIV-infected Thai population pretreated with AZT and ddC for at least 48 weeks

Study Endpoint: Primary: Percentage of patients achieving sustained undetectable HIV-1 RNA in plasma (Amplicor HIV-1 Moniror)…

A phase two randomized, four arm, open-label, comparative trial to evaluate the efficacy and tolerance of combination antiretroviral therapy with ddI + d4T alone or in combination with either nevirapine, hydroxyurea or both nevirapine and hydroxyurea for the treatment of HIV-1 infection in a Thai study population

Hydroxyurea (HU) blocks DNA synthesis by inhibitoion of the cellular enzyme ribonucleotide reductase. It has been…

A phase III, open label, follow up study to protocol HIV-NAT 002.1 to explore the durability of the antiretroviral efficacy and durability of ddI/d4T and AZT/3TC in a population originally treated with ddI/d4T, and explore the efficacy of adding hydroxyurea to failing therapy with two nucleosides

To determine durability of the virological and immunological responses of participants on study 002.1 who were…

A study of the safety, tolerance and pharmacokinetics of Nelfinavir co-administered with Stavudine (d4T) and Didanosine (ddI) in HIV-exposed infants

The pediatric oral powder formulation of Nelfinavir has been studied in small groups of HIV-infected children